Revenue Growth
Total revenue for Q1 2025 was $8.5 million, representing an 11% increase from Q1 2024's $7.6 million.
Biologics and Drug Delivery Revenue Increase
Revenue for biologics and drug delivery rose by 9% to $4.7 million in Q1 2025, fueled by a $1.2 million increase in product revenue.
Neurosurgery Navigation Revenue Surge
Neurosurgery navigation revenue increased by 70% to $3.3 million in Q1 2025, due to higher sales of new product offerings and an increased customer base.
Gross Margin Improvement
Gross margin for Q1 2025 was 60%, a 1% increase compared to 59% in Q1 2024.
Successful Capital Funding
ClearPoint Neuro secured foundational funding from Oberland Capital, providing flexibility with a new credit facility that includes $32 million net proceeds and potential for $25 million more.
Single Use Consumables Growth
Single use consumables business more than doubled with a 104% growth rate, driven by increased orders from biopharma partners and new product launches.